Agilent's Q3 Bio-analytical Revenues Fall 8 Percent amid 27 Percent Total Revenue Decline | GenomeWeb

This article has been updated from a previous version to include information on the company's stock price.

NEW YORK (GenomeWeb News) - Agilent Technologies yesterday reported that revenues for its Bio-analytical segment declined 8 percent in its third fiscal quarter as total revenues fell 27 percent.

For the three months ended July 31, Agilent posted total revenues of $1.06 billion, a 27 percent falloff from $1.4 billion in the year-ago period but an improvement over analyst estimates of $1.02 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.